Document is current
Any future updates will be listed below
-
Authors
Sozzi, Silvia
Manni, Isabella
Ercolani, Cristiana
Diodoro, Maria Grazia
Bartolazzi, Armando
Spallotta, Francesco
Piaggio, Giulia
Monteonofrio, Laura
Soddu, Silvia
Rinaldo, Cinzia
Valente, Davide https://orcid.org/0000-0001-6397-3641
-
Funding
Funding for this research was provided by:
Fondazione AIRC per la ricerca sul cancro ETS (IG 17739, MFAG-23099)
Lega Italiana per la Lotta Contro i Tumori (2021U0001643)
European Union—NextGenerationEU PNRR-M6C2 Investment 2.1 Enhancement and strengthening of biomedical research in the NHS (NRR-MRI-2022-12376604)
European Union—NextGenerationEU through the Italian Ministry of University and Research under PNRR—M4C2-I1.3 (PE_00000019 “HEAL ITALIA” CUP H83C22000550006, PE_00000019 “HEAL ITALIA” CUP H83C22000550006)
- License Information
-
More Information
Article History
Received: 31 May 2024
Accepted: 11 September 2024
First Online: 28 September 2024
Declarations
:
: The utilization of human pancreatic tumors from the IRE Biobank in our research received approval from Institutional Ethics Committee (Comitato Etico Centrale I.R.C.C.S. Lazio, Sezione IRCCS I.F.O.—Fondazione G.B. Bietti – approval CE/694/15) and all patients signed their informed consent for participation. the relevant institutional review boards or ethics committees, and all human participants provided informed consent.All animal studies were approved by the Institutional Animal Care of IRE and by the Government Committee of National Minister of Health (ethics review numbers: 1056/2015-PR and 362/2021) and conducted according to EU Directive 2010/63/EU and Italian D.L. 2614/2014 for animal experiments following the Institutional Guidelines for Animal Care and Welfare.
: All co-authors have consented the version of manuscript for publication.
: The authors declare that they have no competing interest.
